Source: ERS Lung Science Conference 2021
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Olha Boiko, Ukraine. PP302 – The relationship between the level of C-reactive protein and the general cardiovascular risk in patients with COPD and hypertension. ERS Lung Science Conference 2021

Member's Comments

No comment yet.

Related content which might interest you: LSC - 2021 - The relationship between the level of C-reactive protein and the general cardiovascular risk in patients with COPD and hypertension Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 C-reactive protein (CRP) as a risk marker in COPD patients with ischaemic heart disease Source: Annual Congress 2008 - Biomarkers and disease assessment in COPD Year: 2008 C-reactive protein levels in COPD according to clinical parameters, smoking behavior and pulmonary hypertension Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases Year: 2012 C-reactive protein levels and clinically important predictive outcomes in stable COPD patients Source: Eur Respir J 2006; 27: 902-907 Year: 2006 Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients Source: ERJ Open Res, 5 (2) 00021-2019; 10.1183/23120541.00021-2019 Year: 2019 Is there a relationship between severity of COPD and C-reactive protein (CRP) levels? Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006 C-reactive protein levels and the risk of COPD in a general population: the Rotterdam study Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007 The association of respiratory health and cardiovascular risk with structural brain disease in patients with COPD Source: International Congress 2018 – COPD and extrapulmonary comorbidities Year: 2018 C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 Thromboprophylaxis and the relationship between C-reactive protein and plasma fibrinogen in patients with acute exacerbations of COPD Source: Eur Respir J 2007; 30: Suppl. 51, 555s Year: 2007 C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD Source: Eur Respir J 2015; 45: 76-86 Year: 2015 Factors affecting C-reactive protein levels in patients with chronic obstructive pulmonary disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Frequency of occurrence of risk factors of cardiovascular diseases and assessment of the total cardiovascular risk in patients with chronic obstructive pulmonary disease (COPD). Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 MPAP/CO-slope during exercise as predictor of mortality in patients at risk for pulmonary hypertension. Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension Year: 2020 The importance of C-reactive protein in patients with acute exacerbation of severe COPD Source: International Congress 2019 – Airway disease-associated exacerbations Year: 2019 Coexisting chronic diseases in COPD – cause of elevated level of C-reactive protein? Source: Annual Congress 2007 - COPD and comorbidity Year: 2007 The study on the association of serum C-reactive protein level with the risk of lung cancer Source: Annual Congress 2009 - Various diagnostic aspects in lung cancer and rare lung tumours Year: 2009 COPD, asthma and C-reactive protein Source: Eur Respir J 2006; 27: 874-876 Year: 2006 Acute exacerbation in COPD and relationship between cardiovascular risk and functional profile Source: International Congress 2018 – Telehealth, home rehabilitation and specific adaptations to exercise interventions in different settings Year: 2018 The association between COPD and cardiovascular disorders Source: International Congress 2017 – COPD and comorbid cardiovascular diseases Year: 2017